Biolife Solutions, Inc. · NASDAQ:BLFS
Biolife Solutions — Investor Presentation (October 2011)
19 slides from Biolife Solutions's investor presentation, Oct 21, 2011
Slide 1: Investor Presentation October 2011
Investor Presentation October 2011 OTCBB: BLFS
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 including, but not limited to, statements about BioLife Solutions, Inc. (the “Company”) and its future operating results, strategies, and product dev
Slide 3: Leading Innovator Serving $500M Market
NEXT- GENERATION PRODUCTS SCALABLE PRODUCTION FACILITY LARGE, GROWING CUSTOMER BASE Proprietary, best-in- class biopreserveration media products for cells, tissues and organs $25MM annual revenue capacity in a scalable GMP facility 300+ customers and key distributors in strategic market segments: Re
Slide 4: Products and Services
cGMP, Serum-free, protein-free biopreservation media products for cells, tissues, and organs HypoThermosol ® CryoStor ® BloodStor ® Contract aseptic media formulation, fill and finish services Hypothermic storage & shipping media Cryopreservation freeze media Cord blood stem cell freeze media Produc
Slide 5: Target Markets
Biobanking Drug Discovery Regenerative Medicine Target Markets Umbilical cord blood banks, adult stem cell banks, tissue banks, biorepositories Pharmaceutical companies, cell suppliers, toxicity testing labs Commercial cell therapy and tissue engineering companies, hospital based stem cell transplan
Slide 6: Regenerative Medicine Opportunity
Regenerative Medicine Opportunity Use of traditional, archaic “home brew” cocktail results in yield loss and limited shelf life of precious cells intended for clinical applications. Developers face increasing quality and regulatory pressure to switch to pre-formulated, engineered media and reagents
Slide 7: BioLife Products Meet The Opportunity
Enable 2x to 3x longer shelf-life of cell and tissue -based clinical therapies - several days! Increase the yield and viability of cells in the clinical dose Pre-formulated Ÿ cGMP Ÿ Serum-free Ÿ Protein-free BioLife Products Meet The Opportunity § §
Slide 8: CryoStor & HypoThermosol In Customer Clinical Trials
Any successful commercial application could result in $1-2M revenue per year CryoStor ® & HypoThermosol ® In Customer Clinical Trials
Slide 9: Rapidly Expanding Market
Regenerative Medicine Market Growth (Billions) Demand for Biopreservation Media (Millions) Rapidly Expanding Market Source: VisionGain Source: Management estimates, Axis Research Mind
Slide 10: Why Our Products Are In High Demand
Outperform all other biopreservation media Highest quality - GMP Customer service BioLife Preserved Cells Competitive Products Why Our Products Are In High Demand
Slide 11: Competition
Home-Brew Biopreservation Media Competition
Slide 12: How Our Products Are Different
BioLife Biopreservation Media Advantages Proprietary formula, optimized to protect cells from low temperature stress Mitigates apoptosis & necrosis Free radical scavengers Energy substrates pH buffers Pre-Formulated - no mixing required cGMP manufactured USP or highest quality components USP sterili
Slide 13: Diverse Customer Base
Estimated 2010 Segment Revenues Regenerative Medicine Drug Discovery BioBanking Distributor Contract Mfg Diverse Customer Base
Slide 14: Customer logos by segment
Drug Discovery Ceuular Dynamics (LL KaLy-Cell IN XENOTECH Regenerative Medicine » *& carpios sasrron™ centocor recearch&development Lonza Biobanking ViACORD Q Reliance Life Sciences cordlife cOMMUNITY BLOOD SERVICES NEgCBB Distributors ® Fisher Scientific VWRES el BioLire SoLuTIONS ()
Slide 15: Proprietary, High-Value Technology
INTELLECTUAL PROPERTY EMBEDDED TECHNOLOGY § 7 issued patents § 5 submitted applications § Over 200 third-party issued and pending patents citing BioLife products Proprietary, High-Value Technology Critical supplier status with leading companies: § Regenerative medicine § Cord blood banks § Suppliers
Slide 16: Revenue Model Key to Record Growth
REVENUE STREAMS HIGHLIGHTS Revenue Model Key to Record Growth Drug Discovery Regnerative Medicine Contract Mfg Distributor Biobanking * Trailing 12 Months
Slide 17: Growth Trend
Growth Trend Record Revenue in Last 5 Quarters
Slide 18: Investment Summary
Investment Summary • Best-in-class, proprietary, first- choice market position • Leading supplier of clinical grade biopreservation media products • BioLife technology is embedded in numerous current & development stage clinical products • Significant revenue upside upon regulatory approval of custo
Slide 19: OTCBB: BLFS
OTCBB: BLFS http://biolifesolutions.com
Biolife Solutions — Investor Presentation (October 2011) on 6ix